Centre Hospitalier de l'Universite de Motreal (CHUM)

Montreal, Quebec H2X 3E4

0 studies enrolling now · 2 studies all time

What they study most

HER2 Positive Breast Cancer, HER2-positive Breast Cancer

Studies at this site

• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Running, not enrolling